Premium
Diabetes is not sufficient justification for IIb/IIIa use in percutaneous coronary intervention
Author(s) -
Hillegass William B.
Publication year - 2015
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26130
Subject(s) - medicine , percutaneous coronary intervention , diabetes mellitus , cardiology , medline , myocardial infarction , endocrinology , political science , law
Key Points Diabetics, particularly insulin treated, have increased risk of ischemic events and bleeding with percutaneous coronary intervention (PCI). The relative risk of atherothrombotic versus bleeding events is higher in diabetics than non‐diabetics. Bivalirudin with provisional IIb/IIIa therapy has less bleeding and lower one‐year mortality than routine IIb/IIIa therapy in diabetics undergoing PCI. IIb/IIIa agents should be reserved for provisional and niche applications during PCI.